Such a phenotype implies TRPM6 may serve as a potential marker to identify tumors with latent immune responsiveness, providing a rationale for combining TRPM6 targeting with immunotherapies to enhance anti-tumor immunity. Here, TRPM6 is linked to neoplasm.